• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

养心汤治疗冠心病心绞痛随机对照试验的系统评价。

Yangxin decoction for the treatment of angina pectoris of coronary heart disease: A systematic review of randomized controlled trial.

机构信息

Second Ward of Cardiology Department, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.

Department of Acupuncture and Moxibustion, Baicheng Medical College, Baicheng, China.

出版信息

Medicine (Baltimore). 2022 Sep 2;101(35):e30394. doi: 10.1097/MD.0000000000030394.

DOI:10.1097/MD.0000000000030394
PMID:36107541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9439739/
Abstract

BACKGROUND

This study assessed the effectiveness of Yangxin Decoction (YXD) in the treatment of coronary heart disease (CHD) patients with angina pectoris (AP).

METHODS

In this study, we systematically and comprehensively searched the PUBMED, EMBASE, Cochrane Library, CNKI, WANGFANG, and VIP databases from their establishment to June 1, 2022. Clinical randomized controlled trials of YXD for the management of AP in patients with CHD were considered for inclusion. The outcomes included the response rate of AP, response rate based on electrocardiogram, and the rate of nitroglycerin use. Two authors independently performed literature selection, data extraction, and methodological quality assessment. Any differences were resolved by a third author through a discussion.

RESULTS

Nine trials involving 819 patients were included. The meta-analysis results showed that YXD significantly improved the response rate of AP (OR = 2.98, 95% CI: 1.96-4.55, I2 = 0%, P < .01) and the response rate based on the electrocardiogram (OR = 1.88, 95% CI: 1.28-2.78, I2 = 26%, P < .01), and significantly reduced the rate of nitroglycerin use (OR = 2.04, 95% CI: 1.19-3.52, I2 = 0%, P = .01).

CONCLUSIONS

The results of this study showed that YXD was effective in the treatment of patients with AP of CHD. Further studies are required to confirm these results.

摘要

背景

本研究评估了养心汤(YXD)治疗冠心病心绞痛(AP)患者的疗效。

方法

本研究系统全面地检索了 PUBMED、EMBASE、Cochrane 图书馆、CNKI、WANGFANG 和 VIP 数据库,检索时间从建库至 2022 年 6 月 1 日。纳入 YXD 治疗 CHD 患者 AP 的临床随机对照试验。结局指标包括 AP 缓解率、心电图缓解率和硝酸甘油使用率。两位作者独立进行文献筛选、数据提取和方法学质量评估。任何分歧均通过讨论由第三位作者解决。

结果

纳入 9 项试验,共 819 例患者。Meta 分析结果显示,YXD 可显著提高 AP 缓解率(OR = 2.98,95%CI:1.96-4.55,I² = 0%,P <.01)和心电图缓解率(OR = 1.88,95%CI:1.28-2.78,I² = 26%,P <.01),显著降低硝酸甘油使用率(OR = 2.04,95%CI:1.19-3.52,I² = 0%,P =.01)。

结论

本研究结果表明,YXD 对 CHD 患者的 AP 有效。需要进一步的研究来证实这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/15dcbe247847/medi-101-e30394-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/a7ca44c8c204/medi-101-e30394-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/a5935fb42cd1/medi-101-e30394-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/8ef0ecf7c644/medi-101-e30394-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/57904ba913c1/medi-101-e30394-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/15dcbe247847/medi-101-e30394-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/a7ca44c8c204/medi-101-e30394-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/a5935fb42cd1/medi-101-e30394-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/8ef0ecf7c644/medi-101-e30394-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/57904ba913c1/medi-101-e30394-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b67/9439739/15dcbe247847/medi-101-e30394-g005.jpg

相似文献

1
Yangxin decoction for the treatment of angina pectoris of coronary heart disease: A systematic review of randomized controlled trial.养心汤治疗冠心病心绞痛随机对照试验的系统评价。
Medicine (Baltimore). 2022 Sep 2;101(35):e30394. doi: 10.1097/MD.0000000000030394.
2
[Tongmai Yangxin Pills in treatment for angina pectoris of coronary heart disease: a systematic review of randomized clinical trails].通脉养心丸治疗冠心病心绞痛:随机临床试验的系统评价
Zhongguo Zhong Yao Za Zhi. 2019 Jun;44(11):2390-2396. doi: 10.19540/j.cnki.cjcmm.20190305.005.
3
Efficacy and safety of Xuefu Zhuyu decoction combined with Western medicine for angina pectoris in coronary heart disease: A protocol for systematic review and meta-analysis.血府逐瘀汤联合西药治疗冠心病心绞痛的有效性和安全性的系统评价和荟萃分析方案。
Medicine (Baltimore). 2020 Dec 11;99(50):e23195. doi: 10.1097/MD.0000000000023195.
4
Efficacy and safety of Xinkeshu in the treatment of angina pectoris of coronary heart disease: A protocol for systematic review and meta-analysis.欣科舒治疗冠心病心绞痛的疗效及安全性的系统评价和 Meta 分析方案
Medicine (Baltimore). 2021 Oct 8;100(40):e27407. doi: 10.1097/MD.0000000000027407.
5
[Network Meta-analysis of Yiqi Huoxue Chinese patent medicine for coronary heart disease with angina pectoris].[益气活血类中成药治疗冠心病心绞痛的网状Meta分析]
Zhongguo Zhong Yao Za Zhi. 2019 May;44(9):1927-1937. doi: 10.19540/j.cnki.cjcmm.20190114.001.
6
[Systematic evaluation on efficacy and safety of Gingko Ketone Ester Dropping Pills in treatment of angina pectoris and coronary heart disease].银杏酮酯滴丸治疗心绞痛及冠心病的疗效与安全性系统评价
Zhongguo Zhong Yao Za Zhi. 2021 May;46(9):2317-2324. doi: 10.19540/j.cnki.cjcmm.20201230.502.
7
[Effectiveness and safety of Kudiezi injection in treating coronary angina pectoris: systematic review and Meta-analysis of randomized controlled trials].苦碟子注射液治疗冠状动脉粥样硬化性心脏病心绞痛的有效性与安全性:随机对照试验的系统评价与Meta分析
Zhongguo Zhong Yao Za Zhi. 2018 Oct;43(20):4138-4151. doi: 10.19540/j.cnki.cjcmm.20180611.014.
8
A Chinese patent medicine Salvia miltiorrhiza depside salts for infusion combined with conventional treatment for patients with angina pectoris: A systematic review and meta-analysis of randomized controlled trials.丹参多酚酸盐注射液联合常规疗法治疗心绞痛的系统评价和 Meta 分析。
Phytomedicine. 2017 Feb 15;25:100-117. doi: 10.1016/j.phymed.2017.01.002. Epub 2017 Jan 6.
9
Sini decoction as an adjuvant therapy for angina pectoris: a systematic review of randomized controlled trials.四逆汤作为心绞痛辅助治疗的随机对照试验系统评价
J Tradit Chin Med. 2017 Feb;37(1):12-22. doi: 10.1016/s0254-6272(17)30021-3.
10
[Shensong Yangxin Capsules in the adjuvant treatment of stable angina pectoris:a Meta-analysis and trial sequential analysis].参松养心胶囊辅助治疗稳定型心绞痛的Meta分析与试验序贯分析
Zhongguo Zhong Yao Za Zhi. 2019 Sep;44(17):3816-3824. doi: 10.19540/j.cnki.cjcmm.20190624.503.

本文引用的文献

1
Meta-Analysis of the Effect of Honghua Injection in the Treatment of Coronary Heart Disease Angina Pectoris.红花注射液治疗冠心病心绞痛疗效的Meta分析
Evid Based Complement Alternat Med. 2022 May 25;2022:4537043. doi: 10.1155/2022/4537043. eCollection 2022.
2
Effectiveness and safety of acupuncture for angina pectoris: An overview of systematic reviews.针刺治疗心绞痛的有效性和安全性:系统评价概述
Integr Med Res. 2022 Sep;11(3):100864. doi: 10.1016/j.imr.2022.100864. Epub 2022 Apr 6.
3
Correlation and mechanism between cardiac magnetic resonance imaging and oral streptococcus count in patients with primary microvascular angina pectoris.
原发性微血管性心绞痛患者心脏磁共振成像与口腔链球菌计数的相关性及其机制。
Medicine (Baltimore). 2022 Mar 25;101(12):e29060. doi: 10.1097/MD.0000000000029060.
4
[Clinical comprehensive evaluation of Guanxin Shutong Capsules in treatment of coronary heart disease angina pectoris with heart blood stasis syndrome].冠心舒通胶囊治疗冠心病心绞痛心血瘀阻证的临床综合评价
Zhongguo Zhong Yao Za Zhi. 2022 Mar;47(6):1469-1475. doi: 10.19540/j.cnki.cjcmm.20211118.501.
5
Efficacy of Yangxin Recipe in Combination with Conventional Western Medicine in Treatment of Angina Pectoris of Coronary Heart Disease.养心方联合常规西药治疗冠心病心绞痛的疗效。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221076152. doi: 10.1177/10760296221076152.
6
The Material Basis and Mechanism of Xuefu Zhuyu Decoction in Treating Stable Angina Pectoris and Unstable Angina Pectoris.血府逐瘀汤治疗稳定型心绞痛和不稳定型心绞痛的物质基础及作用机制
Evid Based Complement Alternat Med. 2022 Jan 31;2022:3741027. doi: 10.1155/2022/3741027. eCollection 2022.
7
Comparison of Buyang Huanwu granules and Naoxintong capsules in the treatment of stable angina pectoris: rationale and design of a randomized, blinded, multicentre clinical trial.补阳还五颗粒与脑心通胶囊治疗稳定性心绞痛的比较:一项随机、双盲、多中心临床试验的原理和设计。
Trials. 2022 Jan 21;23(1):65. doi: 10.1186/s13063-021-05914-1.
8
Effects of Shen-Yuan-Dan on Periprocedural Myocardial Injury and the Number of Peripheral Blood Endothelial Progenitor Cells in Patients with Unstable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention.参元丹对择期行经皮冠状动脉介入治疗的不稳定型心绞痛患者围手术期心肌损伤及外周血内皮祖细胞数量的影响
Evid Based Complement Alternat Med. 2022 Jan 7;2022:9055585. doi: 10.1155/2022/9055585. eCollection 2022.
9
Overview of Microvascular Angina Pectoris and Discussion of Traditional Chinese Medicine Intervention.微血管性心绞痛概述及中医干预探讨
Evid Based Complement Alternat Med. 2022 Jan 5;2022:1497722. doi: 10.1155/2022/1497722. eCollection 2022.
10
[Clinical comprehensive evaluation of Naoxintong Capsules in treatment of cerebral infarction with Qi deficiency and blood stasis syndrome and coronary heart disease angina pectoris].脑心通胶囊治疗气虚血瘀型脑梗死及冠心病心绞痛的临床综合评价
Zhongguo Zhong Yao Za Zhi. 2021 Dec;46(23):6087-6095. doi: 10.19540/j.cnki.cjcmm.20210930.504.